Second Interim Analysis on ILLUMENATE Global Study

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics’ Stellarex drug-coated balloon at NCVH

COLORADO SPRINGS, Colo., June 01, 2016 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ: SPNC ) today announced that Dr. Prakash Krishnan of Mount Sinai Medical Center, New York, NY presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons annual conference in New Orleans, Louisiana. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex™ drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.

Interim results from 220 patients (247 lesions) of the 371 patients enrolled demonstrated a primary patency rate of 90.3% at day 360 and 86.5% at day 365. Primary patency is a key and objective indicator of clinical effectiveness. Freedom from clinically-driven TLR was 93.9% at both day 360 and 365. These interim results, which include a larger number of patients, are consistent with the initial ILLUMENATE Global 12-month interim analysis and the ILLUMENATE First-In-Human Study results.

“The patency rates from this interim data are top-tier and compare well with the highest DCB patency rates in comparable clinical studies. The fact that these results were achieved with a low-dose DCB is especially compelling. This analysis supports the promising data generated in the First-In-Human study, and I look forward to seeing the randomized data later this year,” said Dr. Krishnan.

“Spectranetics is committed to providing our customers with robust, high quality clinical data in a timely manner to facilitate evidence-based decisions. We are proud to have collaborated with some of the top opinion leaders in the United States and Europe, and are pleased that the second interim analysis supports our top-tier ILLUMENATE First-in-Human Study data,” said Scott Drake, President and CEO.

The ILLUMENATE Global Study is being conducted with a high level of rigor including angiographic and duplex ultrasound core lab assessments, as well as an independent clinical events committee (CEC) to adjudicate adverse events.

The Stellarex DCB is designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease. Spectranetics launched the device in Europe in January 2015, with U.S. commercialization anticipated in the 2017 timeframe.

About the Stellarex Drug-coated Balloon Platform

The Stellarex drug-coated balloon (DCB) platform is designed to treat peripheral arterial disease. The Stellarex DCB uses EnduraCoat™ technology, a durable, uniform coating designed to prevent drug loss during transit and facilitate controlled, efficient drug delivery to the treatment site. The Stellarex DCB platform received CE mark to be marketed in the European Union in December 2014. It is not for sale in the United States. Spectranetics looks forward to releasing additional analysis on the Stellarex DCB later this year.

About ILLUMENATE Global Study

The ILLUMENATE Global Study is a prospective, single-arm, multicenter study that enrolled 371 patients at 37 centers in Europe, Australia and New Zealand. This study is being conducted with a high level of rigor to ensure data is unbiased and accurate. Oversight includes review by angiographic and duplex ultrasound core laboratories, monitoring of all data and oversight by a clinical events committee and a data safety monitoring board. Follow-up assessments include a duplex ultrasound for patency assessment, functional outcome questionnaires (EQ-5D and WIQ), an ABI and RCC assessment, and adverse event evaluations. Patients will be followed for up to five years.

About ILLUMENATE Clinical Trials

There are five clinical studies evaluating the safety and effectiveness of the Stellarex DCB platform and support United States and Canadian regulatory filings. There are four ILLUMENATE clinical studies in addition to the ILLUMENATE Global Study described above:

  • The ILLUMENATE First-In-Human (FIH) Study was a non-randomized, multicenter study that enrolled 80 patients. In the pre-dilatation arm (n=50), the primary patency rate at 12 months was 89.5% and 80.3% at 24 months. The freedom from clinically driven target lesion revascularization rate at 12 months was 90.0% and 85.8% at 24 months.
  • The ILLUMENATE Pharmacokinetic Study measured the Paclitaxel drug levels in the blood of 25 patients enrolled at two sites.
  • The ILLUMENATE Pivotal Study is a prospective, randomized controlled, multicenter trial with 300 patients enrolled at 43 sites to support U.S. FDA approval. Results are expected to be released later this year.
  • The ILLUMENATE European Randomized Trial is a prospective, randomized controlled, multicenter trial with 328 patients enrolled at 18 sites. Results are expected to be released later this year.

About Spectranetics

The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.

The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit www.spectranetics.com .

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements because they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “look forward,” “strive,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” “enable,” “potential,” and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, clinical trials and regulatory approvals, regulatory or competitive environments, outcome of litigation, our intellectual property and product development. These forward-looking statements include, but are not limited to, statements regarding our competitive position, product development and commercialization schedule, expectation of continued growth and the reasons for that growth, growth rates, strength, integration and product launches, and 2016 outlook and projected results including projected revenue and expenses, net loss and gross margin. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements and to note they speak only as of the date of this news release. These risks and uncertainties may include financial results differing from guidance, increasing competition and consolidation in our industry, the impact of rapid technological change, slower revenue growth and losses, inability to successfully integrate AngioScore and Stellarex into our business and the inaccuracy of our assumptions regarding AngioScore and Stellarex, market acceptance of our technology and products, our inability to manage growth, increased pressure on expense levels resulting from expanded sales, marketing, product development and clinical activities, uncertain success of our strategic direction, dependence on new product development and successful commercialization of new products, loss of key personnel, uncertain success of or delays in our clinical trials, costs of and adverse results in any ongoing or future legal proceedings, adverse impact to our business of healthcare reform and related legislation and regulations, including changes in reimbursements, adverse conditions in the general domestic and global economic markets and volatility and disruption of the credit markets, our inability to protect our intellectual property and intellectual property claims of third parties, availability of inventory and components from suppliers, adverse outcome of FDA inspections, the receipt of FDA clearance and other regulatory approvals to market new products or applications and the timeliness of any clearance and approvals, product defects or recalls and product liability claims, cybersecurity breaches, ability to manufacture sufficient volumes to fulfill customer demand, our dependence on third party vendors, suppliers, consultants and physicians, unexpected delays or costs associated with any planned improvements to our manufacturing processes, risks associated with international operations, lack of cash necessary to satisfy our cash obligations under our outstanding 2.625% Convertible Senior Notes due 2034 and our term loan and revolving loan facilities, our debt adversely affecting our financial health and preventing us from fulfilling our debt service and other obligations, and share price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause our actual results, performance or achievements to materially differ from any anticipated results, performance or achievements, please see our previously filed SEC reports, including those risks set forth in our 2015 Annual Report on Form 10-K, and our Quarterly Report on Form 10-Q for the three months ended March 31, 2016. We disclaim any intention or obligation to update or revise any financial or other projections or other forward-looking statements, whether because of new information, future events or otherwise.

Investor Relations Contacts Zach Stassen Sr. Director of Finance zach.stassen@spnc.com  (719) 447-2292 Michaella Gallina Director of Investor Relations michaella.gallina@spnc.com  (719) 447-2417

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 90

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 57

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Jeff Stern Turns Travel Photography Into a Sensory Memoir

Updated Category News Views 112

Frost in a mountain tent, fermented mare’s milk in a yurt, and coffee in Vietnamese rice paddies are doing more work here than a thousand polished sunset captions ever could. Jeff Stern’s A Change of Scenery, released by Palmetto Publishing on November 17, 2026, comes from a man who spent more than 25 years building brands and then decided the usual labels around...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 118

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 15

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 82

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 108

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading

Top 5 Most Recently Viewed Articles

Kleo Partners with Londis to Revolutionize Retail Convenience

Updated Category News Views 256

Kleo Teams Up with Londis to Improve Convenience Store Operations Kleo, a leading provider of EPOS systems and self-ordering kiosks, is thrilled to announce a new partnership with Londis, one of the premier convenience store chains in the UK. This collaboration marks an important move toward modernizing Londis's operations and enhancing customer experiences through...

Continue Reading
W&T Offshore Sees Production Growth and Impressive Cash Flow

Updated Category News Views 119

W&T Offshore's Third Quarter Performance Highlights W&T Offshore, Inc. (NYSE: WTI) has reported its operational and financial results for the third quarter of 2025. With strong results demonstrating production growth and an impressive cash position, the company declared a dividend of $0.01 per share for the upcoming fourth quarter. Financial Overview The company recorded...

Continue Reading
Examining Sustainability in Grape Seed Extracts Production

Updated Category News Views 172

PLT Health Solutions Unveils Sustainability Report for MegaNatural® Grape Seed Extracts PLT Health Solutions, Inc. has proudly released a comprehensive white paper that delves into the sustainability practices involved in the production of its MegaNatural® grape seed extracts. This insightful document showcases the efforts of California Natural Color, a division of...

Continue Reading
Market Stability Returns as VIX Experiences Significant Drop

Updated Category News Views 126

Understanding the Recent Decline in the VIX The CBOE Volatility Index, commonly known as the VIX, saw a notable decrease of 5%, nearing four-week lows. This decline signifies a shift in market sentiment, reflecting greater stability in investor outlook. The Impact of Political Changes on Volatility With the inauguration of a new U.S. President, the market has reacted...

Continue Reading
AlphaTON Capital Corp. Advances in Cancer Treatment Tokenization

Updated Category News Views 205

AlphaTON Capital Corp. Shares See Significant Gains AlphaTON Capital Corp. (NASDAQ: ATON) has recently garnered attention as its shares experience a notable surge in trading activity. This increase follows the company’s announcement of a non-binding letter of intent to assess the tokenization of single-indication economics for their promising cancer treatment, TT-4,...

Continue Reading